Loading
An experimental PET scan from Xiamen that lights up cancer carrying the TROP2 protein, the target of several antibody-drug conjugates.
68Ga-MY6349 has been studied at the First Affiliated Hospital of Xiamen University, which sponsored its first registered study. In a prospective study of 90 patients with 15 cancer types (Chen et al., Journal of Clinical Investigation 2024; NCT06188468), uptake was generally high but varied between lesions, patients and cancers, and correlated closely with Trop2 expression by immunohistochemistry; in breast cancer, tumour uptake was higher than with 18F-FDG (maximum standardised uptake value 7.2 against 5.4).
In 73 patients with suspected or confirmed breast cancer (Yu et al., Theranostics 2026) it found more malignant lesions than FDG (564 against 436) with fewer false positives (2 against 40), upgraded stage in 6 of 30 initial-staging patients, changed treatment in 4 of those 30 and in 5 of 43 restaging patients. In three patients with triple-negative breast cancer on sacituzumab tirumotecan, early changes in uptake after two cycles matched the later response; the authors call this preliminary. It is an investigational agent in China and not approved anywhere.
A Trop2-specific radiotracer labelled with gallium-68 binds Trop2 on tumour cells, so PET shows where Trop2 is expressed across the body in one scan. Connects to TROP2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
A TROP2 scan may help stage breast cancer and, if the early signal holds, judge whether a TROP2 drug is working. It images visible disease, not residual disease after surgery.
TROP2 can be mapped across the whole body without a biopsy, and the map shows it is not the same everywhere in one person.
Query for this drug: (TITLE:"68Ga-MY6349" OR ABSTRACT:"68Ga-MY6349" OR TITLE:"[68Ga]Ga-MY6349" OR ABSTRACT:"[68Ga]Ga-MY6349" OR TITLE:"Gallium-68 MY6349" OR ABSTRACT:"Gallium-68 MY6349" OR TITLE:"MY6349" OR ABSTRACT:"MY6349") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about 68Ga-MY6349, not a curated reading list.
Shares 68Ga-NOTA-T4, TROP2 PET, PET (positron emission tomography), TROP2.
Shares PET (positron emission tomography) and the tag frontier.
Shares PET (positron emission tomography) and the tag diagnostic.
Shares Triple-negative breast cancer (TNBC) and the tag frontier.
Shares TROP2, Triple-negative breast cancer (TNBC) and the tag frontier.
Shares Triple-negative breast cancer (TNBC) and the tag frontier.
Shares TROP2 PET to choose and sequence TROP2 ADCs, TROP2 PET, Sacituzumab tirumotecan, TROP2.
Shares Triple-negative breast cancer (TNBC) and the tag diagnostic.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/